iBio advances bispecific antibody pipeline targeting pulmonary hypertension in heart failure patients. The biotech company is expanding its therapeutic focus with a novel approach to address this serious complication affecting millions globally. The bispecific antibody program represents a strategic shift in iBio's drug development priorities, combining dual targeting mechanisms to potentially improve treatment outcomes. Heart failure complicated by pulmonary hypertension remains a significant unmet medical need with limited therapeutic options. iBio's rationale centers on addressing the underlying pathophysiology of this condition through innovative antibody engineering. The company's pipeline advancement could position it competitively within the cardiovascular therapeutics market if clinical results support efficacy and safety profiles.
